Market revenue in 2023 | USD 295.9 million |
Market revenue in 2030 | USD 510.8 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase II |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 52.38% in 2023. Horizon Databook has segmented the Middle East & Africa cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Conducting cell and gene therapy clinical trials in MEA offers advantages such as patient diversity; cost advantage, infrastructure, and world-class medical facilities. The only drawback is discrepancies between laws of different regions. Many regions are initiating to adapt to the global standards and collaborating with other global CROs to mark their presence.
For instance, Hassan Labs of Egypt and Saham Group of North Africa joined hands to provide international level of medical expertise across Africa. Many countries are implementing global standards and collaborating with other global CROs to mark their presence.
For instance, in September 2020, CTI Clinical Trial and Consulting Services acquired Clinart to expand its presence in the MEA region. Outsourcing clinical trials to a local CRO in the region with regional language proficiency, local regulatory expertise, patient recruitment & site management would be beneficial for companies trying to gain higher shares in the MEA market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell and gene therapy clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account